Date: 2014-12-16
Type of information: Licensing agreement
Compound: GLPG1205, GLPG2196
Company: Galapagos (Belgium) Janssen Pharmaceutica, a J&J company (USA - NJ)
Therapeutic area: Gastrointestinal diseases - Digestive diseases - Inflammatory diseases
Type agreement: licensing
Action mechanism: GLPG1205 works on GPR84, a novel mechanism of action developed by Galapagos for Inflammatory Bowel Diseases (IBD). Earlier this year, Galapagos presented compelling pre-clinical evidence for GPR84 playing a key role in IBD pathology. G-coupled protein receptor 84 (GPR84) is a free fatty acid protein involved in the regulation of macrophages, monocytes, and neutrophils in the human immune system. Galapagos identified GPR84 as playing a key role in inflammation, using its proprietary target discovery platform. GPR84 is over-expressed in inflammatory disease patients. Galapagos has confirmed using in vitro models that GPR84 inhibition prevents neutrophil and macrophage chemotaxis induced by specific triggers, and in relevant in vivo models that \'1205 prevents IBD disease progression. Novel medicine \'1205 is also the first selective inhibitor of GPR84 to be tested in humans, showing good safety, inhibition of GPR84, and favorable drug-like properties in Phase 1 studies.
Disease: inflammatory bowel disease
Details: * On December 16, 2014, Galapagos announced it has agreed with Janssen Pharmaceutica NV that Galapagos will regain full and unencumbered rights to the entire GPR84 program going forward, which includes the inhibitor GLPG1205 and its backup compound GLPG2196. Galapagos disclosed last year that GLPG1205 showed good safety, target engagement, and favorable drug-like properties in Phase 1 studies in healthy volunteers. Galapagos plans to initiate Phase 2 trial patient recruitment before year end 2014. No further details were disclosed.
Financial terms:
Latest news:
